Abstract:Stable long‐term therapeutic gene expression was achieved in murine liver following vector delivery in the newborn period using a dual AAV–transposase system based on either PB or SB. These results have relevance to treatment of genetic liver disease with neonatal onset. Background Conventional adeno‐associated viral (AAV) vectors, while highly effective in quiescent cells such as hepatocytes in the adult liver, confer less durable transgene expression in proliferating cells owing to episome loss. Sustained therapeutic success is therefore less likely in liver disorders requiring early intervention. We have previously developed a hybrid, dual virion approach, recombinant AAV (rAAV)/piggyBac transposon system capable of achieving stable gene transfer in proliferating hepatocytes at levels many fold above conventional AAV vectors. An alternative transposon system, Sleeping Beauty, has been widely used for ex vivo gene delivery; however liver‐targeted delivery using a hybrid rAAV/Sleeping Beauty approach remains relatively unexplored. Methods We investigated the capacity of a Sleeping Beauty (SB)‐based dual rAAV virion approach to achieve stable and efficient gene transfer to the newborn murine liver using transposable therapeutic cassettes encoding coagulation factor IX or ornithine transcarbamylase (OTC). Results At equivalent doses, rAAV/SB100X transduced hepatocytes with high efficiency, achieving stable expression into adulthood. Compared with conventional AAV, the proportion of hepatocytes transduced, and factor IX and OTC activity levels, were both markedly increased. The proportion of hepatocytes stably transduced increased 4‐ to 8‐fold from <5%, and activity levels increased correspondingly, with markedly increased survival and stable urinary orotate levels in the OTC‐deficient Spfash mouse following elimination of residual endogenous murine OTC. Conclusions The present study demonstrates the first in vivo utility of a hybrid rAAV/SB100X transposon system to achieve stable long‐term therapeutic gene expression following delivery to the highly proliferative newborn mouse liver. These results have relevance to the treatment of genetic metabolic liver diseases with neonatal onset.

Therapeutic liver cell transplantation to treat murine PKU

Therapeutic liver cell transplantation to treat a genetic liver defect

Effect of Molecular Therapeutics on Liver Regeneration in a Murine Model.

Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing

Treatment of a genetic liver disease in mice through transient prime editor expression

Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases

In vivo prime editing of a metabolic liver disease in mice

Novel Therapeutic Modalities For Hepatic Diseases

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Reprogramming Metabolic Pathways in Vivo with CRISPR/Cas9 Genome Editing to Treat Hereditary Tyrosinaemia

Application of CRISPR Technology in the Treatment of Phenylketonuria

Gene Therapy for Inherited Liver Disease: To Add or to Edit

Liver‐directed gene therapy for inherited metabolic diseases

Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1

Potential treatment of liver-related disorders with in vitro expanded human liver precursors.

In Vivo Distribution and Gene Expression of Genetically Modified Hepatocytes after Intrasplenic Transplantation

Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency

Gene Editing Correction of a Urea Cycle Defect in Organoid Stem Cell Derived Hepatocyte-like Cells

Therapeutic Cell Repopulation of the Liver: From Fetal Rat Cells to Synthetic Human Tissues

Stable transduction of the neonatal mouse liver using a hybrid rAAV/sleeping beauty transposon gene delivery system

Genetic Modification of Hepatocytes towards Hepatocyte Transplantation and Liver Tissue Engineering